Human evidence record · Delta sleep-inducing peptide

DSIP and 24-hour sleep-wake behaviour in severe chronic insomnia

The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.

Quick read

Human evidence record

What this study tells us

This study compared groups, which is more informative than an uncontrolled report. The amount of confidence still depends on how the groups were formed, how outcomes were measured and how well bias was controlled.

Who was studied?

Middle-aged people with severe chronic insomnia

How many?

n=14

What happened?

The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.

What stops us overclaiming?

Tiny, old single-investigator study; later double-blind work found only weak effects and little likely therapeutic benefit.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

The study reported improved night sleep, daytime rest and performance, with effects persisting into the first placebo post-treatment night.

Study details

Study designPlacebo-controlled, double-blind clinical trial

PopulationMiddle-aged people with severe chronic insomnia

Sample size14

RouteInjection; exact route/dose not stated in indexed abstract

Regimen / exposureDSIP under placebo-controlled double-blind conditions for seven successive nights

Duration7 nights

ComparatorPlacebo baseline / placebo conditions

Primary endpoint / questionNight sleep, daytime rest, alertness and performance

Safety resultModern systematic safety reporting was not provided.

Key limitationsTiny, old single-investigator study; later double-blind work found only weak effects and little likely therapeutic benefit.

Registry / identifierPMID 3622582

Open Delta sleep-inducing peptide page →Open primary source →